^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Low EMT signature scores

    5ms
    Eleven metabolism‑related genes composed of Stard5 predict prognosis and contribute to EMT phenotype in HCC. (PubMed, Cancer Cell Int)
    We developed a new model based on 11 metabolism-related genes, which predicted the prognosis and response to chemotherapy or immunotherapy for HCC. Notably, we demonstrated for the first time that Stard5 acted as a tumor suppressor by inhibiting metastasis in HCC.
    Journal • IO biomarker
    |
    CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • SOX11 (SRY-Box Transcription Factor 11) • GADD45G (Growth Arrest And DNA Damage Inducible Gamma) • SLC2A1 (Solute Carrier Family 2 Member 1) • ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide) • CFHR3 (Complement Factor H Related 3)
    |
    Low EMT signature scores
    9ms
    First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. (PubMed, Nat Med)
    The combination of durvalumab-tremelimumab with mFOLFOX6 was tolerable with promising clinical activity in MSS mCRC. Clinicaltrials.gov identifier: NCT03202758 .
    P1/2 data • Clinical Trial,Phase II • Journal • Tumor mutational burden • PD(L)-1 Biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • CTAG1B (Cancer/testis antigen 1B)
    |
    RAS mutation • Low EMT signature scores
    |
    Imfinzi (durvalumab) • 5-fluorouracil • Imjudo (tremelimumab) • oxaliplatin • leucovorin calcium